Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy.
Lam SW, Nota NM, Jager A, Bos MM, van den Bosch J, van der Velden AM, Portielje JE, Honkoop AH, van Tinteren H, Boven E; ATX Trial Team. Lam SW, et al. Among authors: bos mm. Clin Cancer Res. 2016 Apr 1;22(7):1611-20. doi: 10.1158/1078-0432.CCR-15-1005. Epub 2016 Jan 28. Clin Cancer Res. 2016. PMID: 26823602
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
Hamberg P, Bos MM, Braun HJ, Stouthard JM, van Deijk GA, Erdkamp FL, van der Stelt-Frissen IN, Bontenbal M, Creemers GJ, Portielje JE, Pruijt JF, Loosveld OJ, Smit WM, Muller EW, Schmitz PI, Seynaeve C, Klijn JG; Dutch Breast Cancer Trialists' Group (BOOG). Hamberg P, et al. Among authors: bos mm. Clin Breast Cancer. 2011 Apr;11(2):103-13. doi: 10.1016/j.clbc.2011.03.003. Epub 2011 Apr 11. Clin Breast Cancer. 2011. PMID: 21569996 Clinical Trial.
Disclosing the Uncertainty Associated with Prognostic Estimates in Breast Cancer.
Engelhardt EG, Pieterse AH, Han PK, van Duijn-Bakker N, Cluitmans F, Maartense E, Bos MM, Weijl NI, Punt CJ, Quarles van Ufford-Mannesse P, Sleeboom H, Portielje JE, van der Hoeven KJ, Woei-A-Jin FJ, Kroep JR, de Haes HC, Smets EM, Stiggelbout AM. Engelhardt EG, et al. Among authors: bos mm. Med Decis Making. 2017 Apr;37(3):179-192. doi: 10.1177/0272989X16670639. Epub 2016 Sep 29. Med Decis Making. 2017. PMID: 27681991
Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.
Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, de Wit R, van den Bergh ACM, Coenen JLLM, Beerlage HP, Hendriks MP, Bos MMEM, van den Berg P, van de Wouw AJ, Spermon R, Boerma MO, Geenen MM, Tick LW, Polee MB, Bloemendal HJ, Cordia I, Peters FPJ, de Vos AI, van den Bosch J, van den Eertwegh AJM, Gerritsen WR. Westgeest HM, et al. Among authors: bos mmem. Eur Urol Focus. 2018 Sep;4(5):694-701. doi: 10.1016/j.euf.2016.09.008. Epub 2016 Oct 13. Eur Urol Focus. 2018. PMID: 28753794 Clinical Trial.
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.
van Rossum AGJ, Kok M, McCool D, Opdam M, Miltenburg NC, Mandjes IAM, van Leeuwen-Stok E, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, van Werkhoven E, Schmidt MK, Oosterkamp HM, Linn SC. van Rossum AGJ, et al. Oncotarget. 2017 Nov 27;8(69):113531-113542. doi: 10.18632/oncotarget.22697. eCollection 2017 Dec 26. Oncotarget. 2017. PMID: 29371927 Free PMC article.
Intensive care admission of cancer patients: a comparative analysis.
Bos MM, Verburg IW, Dumaij I, Stouthard J, Nortier JW, Richel D, van der Zwan EP, de Keizer NF, de Jonge E. Bos MM, et al. Cancer Med. 2015 Jul;4(7):966-76. doi: 10.1002/cam4.430. Epub 2015 Apr 18. Cancer Med. 2015. PMID: 25891471 Free PMC article.
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
van Soest RJ, Nieuweboer AJ, de Morrée ES, Chitu D, Bergman AM, Goey SH, Bos MM, van der Meer N, Hamberg P, de Wit R, Mathijssen RH; Dutch Uro-Oncology Studygroup (DUOS). van Soest RJ, et al. Among authors: bos mm. Eur J Cancer. 2015 Nov;51(17):2562-9. doi: 10.1016/j.ejca.2015.07.037. Epub 2015 Aug 13. Eur J Cancer. 2015. PMID: 26278646 Clinical Trial.
Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, Kessels LW, van Laarhoven HW, Bos MM, van de Velde CJ, Gratama JW, Sieuwerts AM, Martens JW, Foekens JA, Sleijfer S. Onstenk W, et al. Among authors: bos mm. Mol Cancer Ther. 2015 Mar;14(3):821-7. doi: 10.1158/1535-7163.MCT-14-0653. Epub 2014 Dec 31. Mol Cancer Ther. 2015. PMID: 25552367 Clinical Trial.
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS. Eichelberg C, et al. Among authors: bos mm. Eur Urol. 2015 Nov;68(5):837-47. doi: 10.1016/j.eururo.2015.04.017. Epub 2015 May 4. Eur Urol. 2015. PMID: 25952317 Free article. Clinical Trial.
60 results